DK254787A - Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel - Google Patents

Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel

Info

Publication number
DK254787A
DK254787A DK254787A DK254787A DK254787A DK 254787 A DK254787 A DK 254787A DK 254787 A DK254787 A DK 254787A DK 254787 A DK254787 A DK 254787A DK 254787 A DK254787 A DK 254787A
Authority
DK
Denmark
Prior art keywords
selenazol
benziso
phenyl
treatment
active ingredient
Prior art date
Application number
DK254787A
Other languages
English (en)
Other versions
DK254787D0 (da
Inventor
Michael John Pernham
Original Assignee
Nattermann A & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nattermann A & Cie filed Critical Nattermann A & Cie
Publication of DK254787D0 publication Critical patent/DK254787D0/da
Publication of DK254787A publication Critical patent/DK254787A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK254787A 1986-05-20 1987-05-19 Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel DK254787A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863616923 DE3616923A1 (de) 1986-05-20 1986-05-20 Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on

Publications (2)

Publication Number Publication Date
DK254787D0 DK254787D0 (da) 1987-05-19
DK254787A true DK254787A (da) 1987-11-21

Family

ID=6301205

Family Applications (1)

Application Number Title Priority Date Filing Date
DK254787A DK254787A (da) 1986-05-20 1987-05-19 Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel

Country Status (6)

Country Link
US (1) US4757063A (da)
EP (1) EP0249735A3 (da)
JP (1) JPS62294613A (da)
DE (1) DE3616923A1 (da)
DK (1) DK254787A (da)
PT (1) PT84898B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
JP2553434B2 (ja) * 1992-04-28 1996-11-13 第一製薬株式会社 粒状製剤
ES2145065T3 (es) 1993-10-27 2000-07-01 Daiichi Seiyaku Co Preparacion granular.
AU5513796A (en) * 1995-04-25 1996-11-18 Daiichi Pharmaceutical Co., Ltd. Remedy for acquired immunodeficiency syndrome
ES2177849T3 (es) * 1996-08-27 2002-12-16 Nattermann A & Cie Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
US6379664B1 (en) 1998-09-29 2002-04-30 Board Of Regents University Of Nebraska-Lincoln Composition and method for the prevention and treatment of oxidative damage in ocular tissues
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU3457300A (en) 1999-03-31 2000-10-16 Daiichi Pharmaceutical Co., Ltd. Substrates for thioredoxin reductase
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US20020146698A1 (en) * 2001-04-05 2002-10-10 Genelink, Inc. Kits and methods for assessing oxidative stress
US7211383B2 (en) * 2001-04-05 2007-05-01 Genelink, Inc. Kits and methods for assessing skin health
WO2003024446A1 (en) * 2001-09-11 2003-03-27 Mitsubishi Pharma Corporation Oxidation stress inhibitor and method of measuring oxidation stress
US20030086916A1 (en) * 2001-10-12 2003-05-08 Goligorsky Michael S. Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
DE20116898U1 (de) * 2001-10-15 2002-01-17 FESTO AG & Co., 73734 Esslingen Mikroventil
WO2005017094A2 (en) * 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
US8222283B2 (en) 2005-05-17 2012-07-17 Santen Pharmaceutical Co., Ltd. Method for treating a keratoconjunctival disorder
FR2902002B1 (fr) * 2006-06-12 2010-08-27 Lvmh Rech Composition cosmetique anti-radicaux libres
US20080207679A1 (en) * 2007-02-16 2008-08-28 Noah Berkowitz Glutathione peroxidase mimetics for the treatment of dermatoses
WO2008100628A2 (en) * 2007-02-16 2008-08-21 Synvista Therapeutics, Inc. Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases
JP5314931B2 (ja) * 2007-05-25 2013-10-16 参天製薬株式会社 加齢黄斑変性の予防又は治療剤
EP2251009B9 (en) * 2008-02-28 2014-09-24 Santen Pharmaceutical Co., Ltd Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
PL234776B1 (pl) * 2018-11-30 2020-03-31 Politechnika Wroclawska Chiralna pochodna 2-azabicykloalkanowa ebselenu oraz sposób jej wytwarzania

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027073C2 (de) * 1980-07-17 1985-03-07 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Präparate, enthaltend 2-Phenyl-1,2-benzisoselenazol-3(2H)-on

Also Published As

Publication number Publication date
EP0249735A3 (en) 1990-01-10
PT84898B (pt) 1990-02-08
US4757063A (en) 1988-07-12
DE3616923A1 (de) 1987-11-26
DK254787D0 (da) 1987-05-19
PT84898A (en) 1987-06-01
JPS62294613A (ja) 1987-12-22
EP0249735A2 (en) 1987-12-23

Similar Documents

Publication Publication Date Title
DK254787D0 (da) Farmaceutiske praeparater til behandling af sygdomme foraarsaget af oxidativt stress og indeholdende 2-phenyl.1,2-benziso-selenazol-3(2h)-on som aktiv bestanddel
NO167391C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aromatiske 2-aminoalkyl-1,2-benzoisothiazol-3-(2h)-on-1,1-dioxydderivater.
DK660788A (da) 2,2-difluorcyklopropylethanderivater, fremgangsmaade til deres fremstilling og deres anvendelse som skadedyrsbekaempelsesmiddel
DK0506539T3 (da) heterocykliske alkylamider, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
NO880182D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1, 2-dihydro-3h-indazol-3h-indazol-3-on-derivater.
NO870666D0 (no) Substituerte thienoinidasolderivater, fremgangsmaate til deres fremstilling og farmasoeytiske tilberedninger inneholdende dem og deres anvendelse som magesyresekresjonshemmer.
DK462588D0 (da) 5-hydroxy-3-aminokromanforbindelser, fremgangsmaade til deres fremstilling, farmaceutiske praeparater indeholdende dem og fremgangsmaader til behandling dermed
NO871052D0 (no) 1,1-disubstituerte cyklopropanderivater, fremgangsmaate til deres fremstilling og deres anvendelse.
NO880473L (no) Fremgangsmaate til fremstilling av substituerte 3,4-dihydro-2h-benzopyraner og deres anvendelse som legemiddel.
NO166326C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive 3,7-substituerte-8-oxo-5-thia-1-azabicyclo-(4,2,0)oct-2-en-2-carboxylater.
DK131887A (da) 1,2,3,4-tetrahydro-3-carbamoyl-2-thioxo/oxo-5-pyrimidencarboxylsyre-derivater og deres anvendelse som laegemidler
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
NO862534D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-oxy-4h-3,1-benzoxazin-4-on-derivater og beslektede forbindelser.
DK531387D0 (da) 3-propenylcephemderivater, mellemprodukter til anvendelse ved fremstillingen heraf og praeparater indeholdende foerstnaevnte forbindelser.
NO165104C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1, 1-disubstituerte cyklopropanderivater.
NO883047D0 (no) Substituerte benzimidazoler, fremgangsmaate til deres fremstilling, farmasoeytise tilberedninger inneholdende dem og deres anvendelse.
NO882509D0 (no) Nye pyrazolforbindelser og herbicide preparater inneholdende dem som aktive bestanddeler.
DK635988D0 (da) 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater
NO863460D0 (no) Fremgangsmaate til fremstilling av 6-fenoksymetyl-4-hydroksy-tetrahydropyran-2-on, fremgangsmaate til deres fremstilling, og deres anvendelse som legemiddel, farmasoeytiske preparater og mellomprodukter.
NO883986L (no) Fremgangsmaate for fremstilling av n-(substituert alkyliden)-1,2,3,4-tetrahydro-9-akridinaminer og anvendelse derav som medikamenter.
NO862390D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydropyridinderivater.
NO822801L (no) Fremgangsmaate ved fremstilling av terapeutisk aktivt 2,5 disubstituerte furaner
NO167801C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,2'-bi-1h-imidazolderivater.
NO894516D0 (no) Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.
DK72088D0 (da) Oximethere af 2,6-dioxabicyclo(3.3.0)octanoner og farmaceutiske praeparater til behandling af hjerte- og blodkredsloebssygdomme

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment